TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of Pelvic Floor Exercises During Gestation in the Prevention of Urinary Incontinence and Pelvic Floor Muscle Dysfunction.
Brief Summary: Urinary incontinence is any involuntary loss of urine. During gestation, hormonal and mechanical factors favor the incidence of urinary loss that may persist after delivery in up to 50% of women. Gestational urine loss can be prevented or treated during pregnancy with physical therapy. Pregnancy and delivery have been widely deemed important risk factors that should be assessed while developing preventive and curative treatments for both female urinary incontinence and pelvic floor muscle dysfunction. Pelvic floor muscle exercises, led by skilled physical therapists, can prevent, reduce, or even cure involuntary urine loss as well as pelvic floor muscle dysfunction. Within this framework, developing a low-cost, easy-to-perform method for the treatment of urinary incontinence and pelvic floor muscle dysfunction, with a preventive or curative approach, is considered necessary. The overall objective of this study is to assess the effects of pelvic floor exercises during pregnancy on pelvic floor muscles and urinary continence. Secondary aims include determining whether exercises change pelvic floor muscle function; if changing pelvic floor muscle function reduces the occurrence of urinary incontinence; developing and applying a manual guide; and determining whether the physical therapy guide is well accepted, easily understandable and reproducible.


Options:
A: Arm Label: Study group - Treatment with PFFM; Type: EXPERIMENTAL; Interventions: Procedure: Pelvic floor fascial mobilization | Arm Label: Control group -; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Pelvic floor fascial mobilization; Assigned to Arm(s): Study group - Treatment with PFFM
B: Arm Label: Physiotherapy intervention; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physiotherapy intervention; Assigned to Arm(s): Physiotherapy intervention
C: Arm Label: G1; Type: EXPERIMENTAL; Interventions: Procedure: Pregnants for receive the physical therapy guide | Intervention Type: PROCEDURE; Name: Pregnants for receive the physical therapy guide; Assigned to Arm(s): G1
D: Arm Label: Group Bladder Training; Type: EXPERIMENTAL; Interventions: Other: Bladder Training | Arm Label: Group TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: TMAP | Arm Label: Group Bladder Training + TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Bladder Training + TMAP | Intervention Type: OTHER; Name: Bladder Training; Assigned to Arm(s): Group Bladder Training | Intervention Type: OTHER; Name: TMAP; Assigned to Arm(s): Group TMAP | Intervention Type: OTHER; Name: Bladder Training + TMAP; Assigned to Arm(s): Group Bladder Training + TMAP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of Pelvic Floor Exercises During Gestation in the Prevention of Urinary Incontinence and Pelvic Floor Muscle Dysfunction.
Brief Summary: Urinary incontinence is any involuntary loss of urine. During gestation, hormonal and mechanical factors favor the incidence of urinary loss that may persist after delivery in up to 50% of women. Gestational urine loss can be prevented or treated during pregnancy with physical therapy. Pregnancy and delivery have been widely deemed important risk factors that should be assessed while developing preventive and curative treatments for both female urinary incontinence and pelvic floor muscle dysfunction. Pelvic floor muscle exercises, led by skilled physical therapists, can prevent, reduce, or even cure involuntary urine loss as well as pelvic floor muscle dysfunction. Within this framework, developing a low-cost, easy-to-perform method for the treatment of urinary incontinence and pelvic floor muscle dysfunction, with a preventive or curative approach, is considered necessary. The overall objective of this study is to assess the effects of pelvic floor exercises during pregnancy on pelvic floor muscles and urinary continence. Secondary aims include determining whether exercises change pelvic floor muscle function; if changing pelvic floor muscle function reduces the occurrence of urinary incontinence; developing and applying a manual guide; and determining whether the physical therapy guide is well accepted, easily understandable and reproducible.


Options:
A: Arm Label: Exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Arm Label: non-exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Intervention Type: BEHAVIORAL; Name: preparation of the delivery; Assigned to Arm(s): Exercice, non-exercice
B: Arm Label: Physical & Behavioral Therapy Group; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Therapy (PT) and Behavioral Therapy (BT) | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Therapy (PT) and Behavioral Therapy (BT); Assigned to Arm(s): Physical & Behavioral Therapy Group
C: Arm Label: Postpartum pelvic floor muscle training; Type: EXPERIMENTAL; Interventions: Other: Postpartum pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Postpartum pelvic floor muscle training; Assigned to Arm(s): Postpartum pelvic floor muscle training
D: Arm Label: G1; Type: EXPERIMENTAL; Interventions: Procedure: Pregnants for receive the physical therapy guide | Intervention Type: PROCEDURE; Name: Pregnants for receive the physical therapy guide; Assigned to Arm(s): G1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Essai thérapeutique randomisé Multicentrique en Double Insu, Comparant l'énoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanée Quotidienne, Dans Les Fausses Couches spontanées récurrentes inexpliquées
Brief Summary: Standard investigations fail to reveal any apparent cause in 50% of the cases of recurrent spontaneous abortion. Prothrombotic mechanisms were initially evoked. Factor V Leiden, Prothrombin G20210A mutation and protein S deficiency are implicated in the meta-analysis of Rey (Lancet).However, they do not account for a large number of miscarriages.Gris JC and coworkers (Blood 2004)carried out an open trial, low-molecular-weight heparin versus low-dose aspirin, in women with one fetal loss and with a constitutional thrombophilic disorder. They conclude for a benefit action of Low-molecular-weight heparin. There is actually no trials concerning women with unexplained recurrent abortions and without known thrombophilia. Nevertheless,aspirin or enoxaparin are often prescribed. It is time to assess these practices. We therefore initiate a multisite, double blind randomized study, enoxaparine versus placebo, in women without known thrombophilia, which experienced unexplained recurrent abortions.


Options:
A: Arm Label: enoxaparin fixed; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: enoxaparin adjusted; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin adjusted
B: Arm Label: Granulocyte colony stimulating factor; Type: EXPERIMENTAL; Interventions: Drug: G-CSF | Arm Label: placebo (saline solution); Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): Granulocyte colony stimulating factor | Intervention Type: DRUG; Name: saline solution; Assigned to Arm(s): placebo (saline solution)
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: enoxaparine 40 mg daily | Intervention Type: DRUG; Name: enoxaparine 40 mg daily; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: Klexane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane | Arm Label: Aspirin and Enoxaparine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane and ASA | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): ASA | Intervention Type: DRUG; Name: Klexane; Assigned to Arm(s): Klexane | Intervention Type: DRUG; Name: Klexane and ASA; Assigned to Arm(s): Aspirin and Enoxaparine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.
Brief Summary: The purpose of this study is to evaluate the effectiveness, safety, and tolerability of carisbamate as add-on therapy for the treatment of partial onset seizures in patients with epilepsy.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Carisbamate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Carisbamate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Carisbamate; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Carisbamate; Assigned to Arm(s): 002
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: RWJ 333369 | Intervention Type: DRUG; Name: RWJ 333369; Assigned to Arm(s): 001
C: Intervention Type: DRUG; Name: RWJ-333369; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: RWJ-333369; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Brief Summary: The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.


Options:
A: N/A
B: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
C: Arm Label: Alfuzosin; Type: EXPERIMENTAL; Interventions: Drug: Alfuzosin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alfuzosin; Assigned to Arm(s): Alfuzosin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Silodosin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Silodosin 4 mg | Arm Label: Silodosin 8 mg; Type: EXPERIMENTAL; Interventions: Drug: Silodosin 8 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Silodosin 8 mg; Assigned to Arm(s): Silodosin 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Silodosin 4 mg; Assigned to Arm(s): Silodosin 4 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Parallel Group, Double-blind, Double-dummy, Active Comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of PGL4001 vs GnRH-agonist for Pre-operative Ttt of Symptomatic Uterine Myomas
Brief Summary: This trial will assess the efficacy and safety of PGL4001 versus GnRH agonist, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo, drug free period | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin, drug free period | Intervention Type: DRUG; Name: PGL4001, placebo, drug free period; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin, drug free period; Assigned to Arm(s): B
B: Arm Label: A (PGL4001 5 mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: C (GnRH-agonist); Type: ACTIVE_COMPARATOR; Interventions: Drug: leuprorelin | Intervention Type: DRUG; Name: PGL4001; Assigned to Arm(s): A (PGL4001 5 mg), B (PGL4001 10mg) | Intervention Type: DRUG; Name: leuprorelin; Assigned to Arm(s): C (GnRH-agonist)
C: Arm Label: A (PGL4001 5mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 (ulipristal) and iron | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 (ulipristal) and iron | Arm Label: C (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: PGL4001 matching placebo and iron | Intervention Type: DRUG; Name: PGL4001 (ulipristal) and iron; Assigned to Arm(s): A (PGL4001 5mg) | Intervention Type: DRUG; Name: PGL4001 matching placebo and iron; Assigned to Arm(s): C (placebo) | Intervention Type: DRUG; Name: PGL4001 (ulipristal) and iron; Assigned to Arm(s): B (PGL4001 10mg)
D: Arm Label: ulipristal acetate -20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 20 mg | Arm Label: ulipristal acetate - 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pre-ulipristal acetate 10 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-ulipristal acetate 20 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ulipristal acetate 20 mg; Assigned to Arm(s): ulipristal acetate -20 mg | Intervention Type: DRUG; Name: ulipristal acetate 10 mg; Assigned to Arm(s): ulipristal acetate - 10 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Parallel Group, Double-blind, Double-dummy, Active Comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of PGL4001 vs GnRH-agonist for Pre-operative Ttt of Symptomatic Uterine Myomas
Brief Summary: This trial will assess the efficacy and safety of PGL4001 versus GnRH agonist, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo, drug free period | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin, drug free period | Intervention Type: DRUG; Name: PGL4001, placebo, drug free period; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin, drug free period; Assigned to Arm(s): B
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: ulipristal acetate -20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 20 mg | Arm Label: ulipristal acetate - 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pre-ulipristal acetate 10 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-ulipristal acetate 20 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ulipristal acetate 20 mg; Assigned to Arm(s): ulipristal acetate -20 mg | Intervention Type: DRUG; Name: ulipristal acetate 10 mg; Assigned to Arm(s): ulipristal acetate - 10 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: A (PGL4001 5 mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: C (GnRH-agonist); Type: ACTIVE_COMPARATOR; Interventions: Drug: leuprorelin | Intervention Type: DRUG; Name: PGL4001; Assigned to Arm(s): A (PGL4001 5 mg), B (PGL4001 10mg) | Intervention Type: DRUG; Name: leuprorelin; Assigned to Arm(s): C (GnRH-agonist)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.
Brief Summary: Universal rotavirus vaccination program for infants born in Brest after February 2007, applied by the Centers for Maternal and Infant Health Protection, pediatricians and general practitioners.

Prospective surveillance of hospitalizations for gastroenteritis within the Pediatric Units of Brest University Hospital with systematic testing for Rotavirus.

Evaluation of the impact of the vaccination program on rotaviral gastroenteritis hospitalizations from 2007-2008 and 2008-2009, by comparison with epidemiological data from 2002-2007 in the absence of vaccination.

The principal judgement criterion is the number of pediatric hospitalizations for rotaviral GEA during the 2008-2009 epidemic in children A) under the age of 2 and B) residing in the suburbs of Brest.


Options:
A: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' liquid human rotavirus vaccine 444563, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' liquid human rotavirus vaccine 444563; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Infanrix™; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV); Assigned to Arm(s): Placebo Group, Rotarix Group
B: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
C: Arm Label: Rotavin; Type: EXPERIMENTAL; Interventions: Drug: Rotavin | Intervention Type: DRUG; Name: Rotavin; Assigned to Arm(s): Rotavin
D: Arm Label: 1; Type: OTHER; Interventions: Biological: Rotateq vaccine | Intervention Type: BIOLOGICAL; Name: Rotateq vaccine; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Influence of Physical Exercise on Endothelial Function in Pregnant Women: Randomized Clinical Trial
Brief Summary: The purpose of this study is to determine the effect of regular aerobic exercise on endothelial function in pregnancy.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Regular aerobic physical exercise | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Activities of daily living | Intervention Type: BEHAVIORAL; Name: Regular aerobic physical exercise; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Activities of daily living; Assigned to Arm(s): II
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Physical exercise | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Physical exercise | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physical exercise; Assigned to Arm(s): 2, 3
C: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise group | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise group; Assigned to Arm(s): Exercise group
D: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics

Answer: A